Tag: CMC

Managing Bioavailability Risks During Technology Transfer: An Actionable Playbook In the highly regulated world of pharmaceutical manufacturing, one significant concern that can surface during the technology transfer phase is the…

Strategies to Address Stability Failures During Tech Transfer in Formulation Development Formulation development is a critical phase in drug manufacturing, particularly during tech transfer when production processes scale up. Failing…

Strategies for Redesigning Formulation to Address Scalability Issues in Early Development In pharmaceutical research and drug development, early-stage formulators often encounter the challenge of prototypes that are not scalable. This…

Managing Stability Failures in Formulation During Technical Transfer In the context of pharmaceutical development, achieving and maintaining stability targets during tech transfer is critical for regulatory compliance and product reliability.…

Strategies to Address Late-Stage Excipient Incompatibility During Tech Transfer In the dynamic landscape of pharmaceutical formulation, late-stage excipient incompatibility can pose significant challenges during tech transfers. Such incompatibilities often remain…

Managing Excipient Incompatibility Issues During IND/NDA Submissions Excipient incompatibility identified late during IND/NDA filing can pose significant risks to the successful registration and market launch of pharmaceutical products. These challenges…

Mitigating Bioavailability Risk During Tech Transfer: A Practical Playbook The transfer of technology in pharmaceutical manufacturing, particularly during formulation development, often brings to the forefront several risks. Chief among these…

Tackling Scalability Challenges in Early Development: Regulatory Insights for Formulation Data Navigating the complexities of formulation development requires a strategic approach, especially when prototypes prove not scalable during early development…

Strategies for Addressing Scale-Up Issues in Early Formulation Development In pharmaceutical development, encountering a prototype that is not scalable poses significant risks, particularly during the critical transition from formulation development…

Addressing Late-Stage Excipient Incompatibility in Early Development to Avoid Reformulation Challenges In pharmaceutical manufacturing, identifying excipient incompatibility during the early development stages is crucial for successful formulation development. Late detection…

Addressing Unexplained Dissolution Variability During Tech Transfer Dissolution variability during tech transfer poses significant challenges for pharmaceutical companies, particularly when faced with late-stage reformulation. These variances can stem from numerous…

Addressing Formulation Stability Failures During IND/NDA Filings: A Practical Playbook In the complex world of pharmaceutical development, there are few more challenging situations than a formulation failing to meet stability…